BCL2 and Parkinson disease: Madecassoside decreases the depletion of dopamine and its metabolites, and the malondialdehyde (MDA) level significantly enhances the striatal BDNF level and modulates the ratio of Bcl-2/Bax in MPTP-induced PD in Wistar rats for Parkinson’s disease research (Shahpiri et al., 2016).